Skip to content
FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give More Than 350 Flagstaff Children New Winter Coats[9:30:00 AM ET]FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give 350 Bay City Children New Winter Coats[9:30:00 AM ET]APH$80.00+1.79(+2.29%)Industrial Growth Partners Announces Sale of AdvancedPCB Industrial Growth Partners ("IGP") is pleased to announce that it has entered into a definitive agreement to sell AdvancedPCB Holdings, LLC...[9:27:00 AM ET]BLGO$0.07-0.00(-3.62%)BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success[9:25:00 AM ET]TWOSF$0.24-0.00(-0.04%)T2 Metals to Attend the 52nd Annual New Orleans Investment Conference[9:25:00 AM ET]MOB$3.32+0.03(+0.91%)Mobilicom to Showcase Cybersecure Portfolio Highlighting Newly Launched SwarmiX at ARC WEPTAC Conference[9:22:00 AM ET]COSM$0.25+0.02(+6.82%)Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target[9:20:00 AM ET]MGN$2.83-0.23(-7.52%)Megan Holdings Limited Announces Pricing of Up to $7.5 Million Follow-on Public Offering[9:20:00 AM ET]ADSE$9.36+0.06(+0.65%)ADS-TEC Energy Advances One of Europe's Largest Battery Storage Projects as Building Permit Nears[9:18:00 AM ET]ELS$58.45-1.04(-1.75%)ELS Declares Fourth Quarter 2026 Dividend On October 27, 2026, the Board of Directors of Equity LifeStyle Properties, Inc. (NYSE: ELS) (referred to herein as "we," "us," and "our") declared a ...[9:18:00 AM ET]IREN$27.27-0.18(-0.64%)IREN and Wingspire Equipment Finance Complete $363 Million Financing for High-Density AI Compute Assets[9:17:00 AM ET]GSAT$83.91+0.01(+0.01%)XCOM RAN Wins the Gold Stevie® 2026 Award for Technology Excellence[9:16:00 AM ET]CYAB$0.13-0.00(-0.53%)Cyabra Finds Coordinated Inauthentic Activity in Five of Six Competitive Midterm Races, Affecting Candidates from Both Parties[9:15:00 AM ET]AIBT$0.000.00(0.00%)AIBotics Provides PHILL ROBOT™ Manufacturing Update as 3DX Industries Supports Five-Unit Pilot[9:15:00 AM ET]LGVN$1.79+0.06(+3.42%)Longeveron Announces Engagement of Lucid Capital Markets[9:15:00 AM ET]QNC$1.10+0.01(+0.92%)Quantum eMotion to Showcase Quantum-Safe Cybersecurity Portfolio at World Quantum Cannes Festival November 17-18, 2026[9:15:00 AM ET]

PALI · NASDAQ

Palisade Bio, Inc.

$1.17 -0.03 (-2.09%)

Company overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of a digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$204M
Employees
8
Headquarters
Carlsbad, CA
CEO
J. D. Finley
Listed
March 30, 2007
P/E
-1.10
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$26.5M
EBITDA
-$26.6M
Net income
-$24.2M
EPS
-$1.06
Total assets
$133M
Total debt
$0.00
Earnings yield
-90.74%

Revenue segmentation

By product

No annual segmentation.

By region

No geographic segmentation.

Price chart

1.131.431.732.032.33
PALI 1D NASDAQ O1.22H1.26L1.17C1.20-0.03 (-2.85%)Vol1.48M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Source
Date
Type
Ticker Type Headline Source Published

Loading headlines…

FAQ

Questions about Palisade Bio, Inc.

What does Palisade Bio, Inc. do?
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of a digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
What is PALI's market cap?
Palisade Bio, Inc. (PALI) is a listed stock with a live quote. The latest market cap on this page is $204M.
Where is Palisade Bio, Inc. headquartered?
Palisade Bio, Inc. is headquartered in Carlsbad, CA.
How do I get PALI news from the API?
Call GET /v1/news?tickers=PALI. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does PALI news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PALI, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the PALI price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.